Answers are grounded in this paper and cite their sources.
Nanomedicine has emerged as a transformative field that integrates nanotechnology with biomedical sciences to improve disease diagnosis, targeted drug delivery, and therapeutic efficacy. This review provides a comprehensive overview of recent advances in nanomaterial-based strategies for the prevention, diagnosis, and treatment of major human diseases, including cancer, cardiovascular disorders, diabetes mellitus, Alzheimer's disease, chronic kidney disease, respiratory illnesses, and infectious diseases. Various nanoplatforms, such as lipid-based nanoparticles, polymeric nanoparticles, metallic nanoparticles, quantum dots, dendrimers, and carbon-based nanomaterials, are discussed with respect to their physicochemical properties, synthesis approaches, biological interactions, and clinical applications. Particular emphasis is placed on their ability to enhance drug bioavailability, improve tissue-specific targeting, overcome biological barriers, enable controlled drug release, and support theranostic applications. The review also highlights recent progress in clinically approved nanomedicines and ongoing clinical trials, demonstrating the growing translational potential of nanoparticle-based therapeutics. Furthermore, environmentally sustainable green synthesis approaches and biomaterial-assisted nanoparticle fabrication are examined as promising alternatives to conventional chemical synthesis. Despite remarkable advances, significant challenges remain regarding long-term toxicity, biodistribution, large-scale manufacturing, regulatory approval, and clinical translation. Current evidence underscores the necessity for standardized safety evaluation, robust pharmacokinetic characterization, and harmonized regulatory frameworks to facilitate successful commercialization. Overall, nanotechnology represents a cornerstone of precision medicine, offering multifunctional platforms capable of integrating diagnosis, targeted therapy, and real-time monitoring. Continued interdisciplinary research, technological innovation, and rigorous clinical validation are expected to accelerate the development of safe, effective, and sustainable nanomedicines, thereby reshaping future healthcare and improving patient outcomes across a broad spectrum of diseases.
No takes yet. Share an insight, caveat, or question.
Kanipandian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: